Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cortecs International expects £50 million revenues from Helisal

This article was originally published in Clinica

Executive Summary

An exclusive US distribution deal between Cortecs International and Boehringer Mannheim for Cortecs' doctors' office Helisal Rapid Blood tests for H pylori is expected to generate revenues of at least $24 million over the next six years. The 10-year agreement follows a similar £19 million deal signed earlier this year which excluded the US. Under this latest agreement Boehringer has the first right to negotiate for new Helisal products in the US and a right to improvements to the rapid blood test.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel